Trial Profile
Efficacy and safety of immunoglobulin associated with rituximab versus rituximab alone in Childhood-Onset steroid-dependent nephrotic syndrome
Status:
Suspended
Phase of Trial:
Phase II/III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- Acronyms RITUXIVIG
- 01 Oct 2021 Planned End Date changed from 3 Apr 2023 to 4 Nov 2022.
- 01 Oct 2021 Status changed from recruiting to suspended.
- 19 May 2020 Planned End Date changed from 3 Apr 2022 to 3 Apr 2023.